What is HC Wainwright’s Forecast for PRAX Q1 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Praxis Precision Medicines in a note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($3.18) for the quarter, down from their prior estimate of ($2.96). HC Wainwright currently has a “Buy” rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($3.64) EPS, Q3 2025 earnings at ($4.15) EPS, Q4 2025 earnings at ($4.16) EPS, FY2025 earnings at ($15.13) EPS, Q1 2026 earnings at ($4.39) EPS, Q2 2026 earnings at ($4.82) EPS, Q3 2026 earnings at ($4.89) EPS, Q4 2026 earnings at ($4.90) EPS, FY2026 earnings at ($18.99) EPS, FY2027 earnings at ($15.64) EPS, FY2028 earnings at ($15.64) EPS and FY2029 earnings at $23.38 EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Friday, February 28th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The firm had revenue of $7.48 million during the quarter, compared to analyst estimates of $0.36 million.

A number of other research analysts have also issued reports on the stock. Needham & Company LLC lowered their target price on shares of Praxis Precision Medicines from $150.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Praxis Precision Medicines in a research report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price target on the stock. Wedbush lowered shares of Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a research report on Friday, February 28th. Truist Financial decreased their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Robert W. Baird decreased their price target on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.80.

Praxis Precision Medicines Trading Up 7.9 %

NASDAQ:PRAX opened at $36.21 on Wednesday. Praxis Precision Medicines has a 1 year low of $30.01 and a 1 year high of $91.83. The firm’s fifty day simple moving average is $74.53 and its 200 day simple moving average is $69.53. The firm has a market capitalization of $674.88 million, a PE ratio of -3.52 and a beta of 2.65.

Institutional Trading of Praxis Precision Medicines

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Praxis Precision Medicines in the fourth quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Praxis Precision Medicines in the fourth quarter valued at $48,000. US Bancorp DE lifted its stake in Praxis Precision Medicines by 35.9% in the third quarter. US Bancorp DE now owns 2,289 shares of the company’s stock valued at $132,000 after acquiring an additional 605 shares during the last quarter. Graham Capital Management L.P. acquired a new stake in Praxis Precision Medicines in the fourth quarter valued at $209,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Praxis Precision Medicines in the fourth quarter valued at $215,000. Institutional investors and hedge funds own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.